Literature DB >> 6481186

Resistance of Vibrio vulnificus to serum bactericidal and opsonizing factors: relation to virulence in suckling mice and humans.

D E Johnson, F M Calia, D M Musher, A Goree.   

Abstract

Vibrio vulnificus causes soft-tissue infections, gastrointestinal disease, and severe sepsis in humans. Bacterial and host factors in virulence have remained poorly defined. We found that blood culture isolates of V. vulnificus were completely resistant to the bactericidal effects of 10% normal human serum, in contrast to soft-tissue and environmental isolates that showed a mean 2.6 log10 decline during 120 min of incubation. Following opsonization by 10% normal human serum, mean uptake of blood isolates by normal human polymorphonuclear leukocytes during 20 min of incubation in vitro was 45.8% compared with 83.2% for isolates from other sites. Blood isolates were lethal for suckling mice (mean LD50, 1.3 X 10(6)) in contrast with isolates from other sites, which were less virulent (mean LD50, 1 X 10(9)); lethality correlated well with bacteremia at 6 hr. These studies show a close correlation between bacterial virulence for humans and suckling mice and suggest that resistance to the bactericidal and opsonizing effects of normal human serum may be important factors governing that virulence.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6481186     DOI: 10.1093/infdis/150.3.413

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Virulence characteristics of clinical and environmental isolates of Vibrio vulnificus.

Authors:  G N Stelma; A L Reyes; J T Peeler; C H Johnson; P L Spaulding
Journal:  Appl Environ Microbiol       Date:  1992-09       Impact factor: 4.792

2.  Pulsed-field gel electrophoresis and ribotype profiles of clinical and environmental Vibrio vulnificus isolates.

Authors:  M L Tamplin; J K Jackson; C Buchrieser; R L Murphree; K M Portier; V Gangar; L G Miller; C W Kaspar
Journal:  Appl Environ Microbiol       Date:  1996-10       Impact factor: 4.792

3.  Bactericidal effects of toluidine blue-mediated photodynamic action on Vibrio vulnificus.

Authors:  Tak-Wah Wong; Yin-Yi Wang; Hamm-Ming Sheu; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Toxic and enzymatic activities of Vibrio vulnificus biotype 2 with respect to host specificity.

Authors:  E G Biosca; C Amaro
Journal:  Appl Environ Microbiol       Date:  1996-07       Impact factor: 4.792

5.  Role of anaerobiosis in capsule production and biofilm formation in Vibrio vulnificus.

Authors:  Britney L Phippen; James D Oliver
Journal:  Infect Immun       Date:  2014-11-17       Impact factor: 3.441

Review 6.  Current perspectives on the epidemiology and pathogenesis of clinically significant Vibrio spp.

Authors:  J M Janda; C Powers; R G Bryant; S L Abbott
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

7.  Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus.

Authors:  S J Devi; U Hayat; J L Powell; J G Morris
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

8.  The type IV leader peptidase/N-methyltransferase of Vibrio vulnificus controls factors required for adherence to HEp-2 cells and virulence in iron-overloaded mice.

Authors:  R N Paranjpye; J C Lara; J C Pepe; C M Pepe; M S Strom
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  The extracellular cytolysin of Vibrio vulnificus: inactivation and relationship to virulence in mice.

Authors:  A C Wright; J G Morris
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

10.  Vibrio vulnificus induces macrophage apoptosis in vitro and in vivo.

Authors:  Takashige Kashimoto; Shunji Ueno; Miyuki Hanajima; Hisae Hayashi; Yukihiro Akeda; Shinichi Miyoshi; Toshiharu Hongo; Takeshi Honda; Nobuyuki Susa
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.